1. Home
  2. SNCY vs DRUG Comparison

SNCY vs DRUG Comparison

Compare SNCY & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sun Country Airlines Holdings Inc.

SNCY

Sun Country Airlines Holdings Inc.

HOLD

Current Price

$21.72

Market Cap

766.5M

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$76.68

Market Cap

856.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNCY
DRUG
Founded
1982
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
766.5M
856.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SNCY
DRUG
Price
$21.72
$76.68
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$19.00
$106.75
AVG Volume (30 Days)
2.4M
125.9K
Earning Date
02-05-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.96
N/A
Revenue
$1,126,769,000.00
N/A
Revenue This Year
$6.07
N/A
Revenue Next Year
$8.15
N/A
P/E Ratio
$22.75
N/A
Revenue Growth
4.74
N/A
52 Week Low
$8.10
$23.18
52 Week High
$22.12
$123.75

Technical Indicators

Market Signals
Indicator
SNCY
DRUG
Relative Strength Index (RSI) 79.72 43.97
Support Level $16.93 $72.08
Resistance Level $18.28 $81.00
Average True Range (ATR) 0.69 4.85
MACD 0.16 -1.57
Stochastic Oscillator 100.00 26.02

Price Performance

Historical Comparison
SNCY
DRUG

About SNCY Sun Country Airlines Holdings Inc.

Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: